Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis

Ali Moustapha, Anjan Gupta, Killian Robinson, Kristopher Arheart, Donald W. Jacobsen, Martin J. Schreiber, Vincent W. Dennis

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Background. Hyperhomocysteinemia is an independent risk factor for atherosclerotic complications in patients with end-stage renal disease, although the mechanisms remain unclear. The major determinants of plasma homocysteine concentration are usually folate, vitamin B12, pyridoxal 5'- phosphate (vitamin B6), and glomerular filtration rate. Methods. We measured factors, including plasma folate, vitamin B12, vitamin B6, creatinine, as well as the dose and duration of dialysis, that might affect plasma homocysteine concentrations in 130 patients on hemodialysis (HD) and compared these observations with those in 46 patients on peritoneal dialysis (PD). Independent determinants of total homocysteine were identified using a multiple logistical regression analysis. Results. Total homocysteine values averaged 29.8 μmol/liter in HD patients, significantly higher than the mean value of 19.9 μmol/liter observed in patients on PD (P < 0.001). The prevalence of hyperhomocysteinemia was 90.8% among HD patients, significantly higher than the prevalence of 67.4% among PD patients. Folate values in HD patients averaged 45.5 nmol/liter and were significantly lower than in PD patients (104.2 nmol/liter, P < 0.001). For patients on HD, the only determinant of total homocysteine concentration was plasma folate (r = - 0.31, P < 0.001). In contrast, for PD patients, total homocysteine did not correlate with plasma folate, vitamin B12, or vitamin B6. Conclusions. Hyperhomocysteinemia is more prevalent and intense in HD patients compared with those on PD. The homocysteine response may become refractory to excess folate supplementation in PD patients.

Original languageEnglish
Pages (from-to)1470-1475
Number of pages6
JournalKidney International
Volume55
Issue number4
DOIs
StatePublished - Apr 14 1999
Externally publishedYes

Fingerprint

Hyperhomocysteinemia
Peritoneal Dialysis
Renal Dialysis
Homocysteine
Folic Acid
Vitamin B 6
Vitamin B 12
Pyridoxal Phosphate
Glomerular Filtration Rate
Chronic Kidney Failure
Dialysis
Creatinine

Keywords

  • Dialysis
  • Folic acid
  • Homocyteine
  • Renal failure
  • Vascular disease

ASJC Scopus subject areas

  • Nephrology

Cite this

Moustapha, A., Gupta, A., Robinson, K., Arheart, K., Jacobsen, D. W., Schreiber, M. J., & Dennis, V. W. (1999). Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney International, 55(4), 1470-1475. https://doi.org/10.1046/j.1523-1755.1999.00378.x

Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. / Moustapha, Ali; Gupta, Anjan; Robinson, Killian; Arheart, Kristopher; Jacobsen, Donald W.; Schreiber, Martin J.; Dennis, Vincent W.

In: Kidney International, Vol. 55, No. 4, 14.04.1999, p. 1470-1475.

Research output: Contribution to journalArticle

Moustapha, A, Gupta, A, Robinson, K, Arheart, K, Jacobsen, DW, Schreiber, MJ & Dennis, VW 1999, 'Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis', Kidney International, vol. 55, no. 4, pp. 1470-1475. https://doi.org/10.1046/j.1523-1755.1999.00378.x
Moustapha A, Gupta A, Robinson K, Arheart K, Jacobsen DW, Schreiber MJ et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney International. 1999 Apr 14;55(4):1470-1475. https://doi.org/10.1046/j.1523-1755.1999.00378.x
Moustapha, Ali ; Gupta, Anjan ; Robinson, Killian ; Arheart, Kristopher ; Jacobsen, Donald W. ; Schreiber, Martin J. ; Dennis, Vincent W. / Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. In: Kidney International. 1999 ; Vol. 55, No. 4. pp. 1470-1475.
@article{627759702c164e31be424e4c3be2de37,
title = "Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis",
abstract = "Background. Hyperhomocysteinemia is an independent risk factor for atherosclerotic complications in patients with end-stage renal disease, although the mechanisms remain unclear. The major determinants of plasma homocysteine concentration are usually folate, vitamin B12, pyridoxal 5'- phosphate (vitamin B6), and glomerular filtration rate. Methods. We measured factors, including plasma folate, vitamin B12, vitamin B6, creatinine, as well as the dose and duration of dialysis, that might affect plasma homocysteine concentrations in 130 patients on hemodialysis (HD) and compared these observations with those in 46 patients on peritoneal dialysis (PD). Independent determinants of total homocysteine were identified using a multiple logistical regression analysis. Results. Total homocysteine values averaged 29.8 μmol/liter in HD patients, significantly higher than the mean value of 19.9 μmol/liter observed in patients on PD (P < 0.001). The prevalence of hyperhomocysteinemia was 90.8{\%} among HD patients, significantly higher than the prevalence of 67.4{\%} among PD patients. Folate values in HD patients averaged 45.5 nmol/liter and were significantly lower than in PD patients (104.2 nmol/liter, P < 0.001). For patients on HD, the only determinant of total homocysteine concentration was plasma folate (r = - 0.31, P < 0.001). In contrast, for PD patients, total homocysteine did not correlate with plasma folate, vitamin B12, or vitamin B6. Conclusions. Hyperhomocysteinemia is more prevalent and intense in HD patients compared with those on PD. The homocysteine response may become refractory to excess folate supplementation in PD patients.",
keywords = "Dialysis, Folic acid, Homocyteine, Renal failure, Vascular disease",
author = "Ali Moustapha and Anjan Gupta and Killian Robinson and Kristopher Arheart and Jacobsen, {Donald W.} and Schreiber, {Martin J.} and Dennis, {Vincent W.}",
year = "1999",
month = "4",
day = "14",
doi = "10.1046/j.1523-1755.1999.00378.x",
language = "English",
volume = "55",
pages = "1470--1475",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis

AU - Moustapha, Ali

AU - Gupta, Anjan

AU - Robinson, Killian

AU - Arheart, Kristopher

AU - Jacobsen, Donald W.

AU - Schreiber, Martin J.

AU - Dennis, Vincent W.

PY - 1999/4/14

Y1 - 1999/4/14

N2 - Background. Hyperhomocysteinemia is an independent risk factor for atherosclerotic complications in patients with end-stage renal disease, although the mechanisms remain unclear. The major determinants of plasma homocysteine concentration are usually folate, vitamin B12, pyridoxal 5'- phosphate (vitamin B6), and glomerular filtration rate. Methods. We measured factors, including plasma folate, vitamin B12, vitamin B6, creatinine, as well as the dose and duration of dialysis, that might affect plasma homocysteine concentrations in 130 patients on hemodialysis (HD) and compared these observations with those in 46 patients on peritoneal dialysis (PD). Independent determinants of total homocysteine were identified using a multiple logistical regression analysis. Results. Total homocysteine values averaged 29.8 μmol/liter in HD patients, significantly higher than the mean value of 19.9 μmol/liter observed in patients on PD (P < 0.001). The prevalence of hyperhomocysteinemia was 90.8% among HD patients, significantly higher than the prevalence of 67.4% among PD patients. Folate values in HD patients averaged 45.5 nmol/liter and were significantly lower than in PD patients (104.2 nmol/liter, P < 0.001). For patients on HD, the only determinant of total homocysteine concentration was plasma folate (r = - 0.31, P < 0.001). In contrast, for PD patients, total homocysteine did not correlate with plasma folate, vitamin B12, or vitamin B6. Conclusions. Hyperhomocysteinemia is more prevalent and intense in HD patients compared with those on PD. The homocysteine response may become refractory to excess folate supplementation in PD patients.

AB - Background. Hyperhomocysteinemia is an independent risk factor for atherosclerotic complications in patients with end-stage renal disease, although the mechanisms remain unclear. The major determinants of plasma homocysteine concentration are usually folate, vitamin B12, pyridoxal 5'- phosphate (vitamin B6), and glomerular filtration rate. Methods. We measured factors, including plasma folate, vitamin B12, vitamin B6, creatinine, as well as the dose and duration of dialysis, that might affect plasma homocysteine concentrations in 130 patients on hemodialysis (HD) and compared these observations with those in 46 patients on peritoneal dialysis (PD). Independent determinants of total homocysteine were identified using a multiple logistical regression analysis. Results. Total homocysteine values averaged 29.8 μmol/liter in HD patients, significantly higher than the mean value of 19.9 μmol/liter observed in patients on PD (P < 0.001). The prevalence of hyperhomocysteinemia was 90.8% among HD patients, significantly higher than the prevalence of 67.4% among PD patients. Folate values in HD patients averaged 45.5 nmol/liter and were significantly lower than in PD patients (104.2 nmol/liter, P < 0.001). For patients on HD, the only determinant of total homocysteine concentration was plasma folate (r = - 0.31, P < 0.001). In contrast, for PD patients, total homocysteine did not correlate with plasma folate, vitamin B12, or vitamin B6. Conclusions. Hyperhomocysteinemia is more prevalent and intense in HD patients compared with those on PD. The homocysteine response may become refractory to excess folate supplementation in PD patients.

KW - Dialysis

KW - Folic acid

KW - Homocyteine

KW - Renal failure

KW - Vascular disease

UR - http://www.scopus.com/inward/record.url?scp=0032941601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032941601&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.1999.00378.x

DO - 10.1046/j.1523-1755.1999.00378.x

M3 - Article

VL - 55

SP - 1470

EP - 1475

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -